ClinicalTrials.gg
CompletedNCT06091579Updated Oct 19, 2023

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

A Phase 1 interventional study of Treprostinil Palmitil Inhalation Powder and Placebo in Healthy Volunteers, sponsored by Insmed Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 10 months ago, and no results have been posted to the registry.
  • Registered 3 years after the study started (first participant enrolled Sep 2020, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of single and multiple doses of treprostinil palmitil inhalation powder in healthy participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is considered by the investigator to be in good general health as determined by medical history, physical examination findings, vital sign measurements, 12-lead (ECG) results, and clinical laboratory test results within normal limits or considered not by the investigator, at screening.

Exclusion criteria

Exclusion Criteria:

  • The participant has an allergy, documented , or to the ingredients or to any of the of treprostinil palmitil inhalation powder or treprostinil.
  • The participant has used any prescription (excluding hormonal ) or over-the-counter medications, including herbal or nutritional supplements, within 14 days before the first dose of study drug and throughout the study.
  • The participant has a history of anaphylaxis, previously documented hypersensitivity reaction to any drug.
  • The participant has had a surgical procedure that required general anesthesia (or equivalent) within 90 days prior to screening.
  • The participant has a \<19.0 or >32.0 kilograms per square meter (kg/m\^2) at screening.
  • The participant has a history of syncope not due to dehydration or vasovagal syncope (eg, congenital cardiac arrhythmias such as Wolff-Parkinson-White syndrome, nodal tachycardia, ventricular tachycardia, etc).
  • The participant has active liver disease or hepatic dysfunction at screening or check-in visits.
  • The participant has a history of (HIV) infection.
  • The participant has a history of abnormal bleeding or bruising.
  • The participant has a history of in the past 5 years, with exception of nonmelanoma skin cancer.
  • The participant has a current history (within the past 12 months) of substance and/or alcohol abuse.
  • The participant is a current user of cigarettes (average of ≥1 cigarette/day) or e-cigarettes within 30 days prior to screening.
  • The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening or before the first dose of study drug or throughout the study.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part A (SAD Cohort 1): TPIP

    Participants in the single ascending dose (SAD) Cohort 1 received a single dose of TPIP at Dose A, Dose B, or Dose C by oral inhalation on Day 1.

    Drug: Treprostinil Palmitil Inhalation Powder

  • Experimental
    Part A (SAD Cohort 2): TPIP or Placebo

    Participants in SAD Cohort 2 received a single dose of TPIP at Dose D or matching placebo by oral inhalation on Day 1.

    Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo

  • Experimental
    Part A (SAD Cohort 3): TPIP or Placebo

    Participants in SAD Cohort 3 received a single dose of TPIP at Dose E or matching placebo by oral inhalation on Day 1.

    Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo

  • Experimental
    Part B (MAD Cohort 1): TPIP or Placebo

    Participants in the multiple ascending dose (MAD) Cohort 1 received TPIP at Dose B, Dose C or matching placebo, once daily (QD) by oral inhalation on Days 1 through 7.

    Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo

  • Experimental
    Part B (MAD Cohort 2): TPIP or Placebo

    Participants in MAD Cohort 2 received TPIP up to Dose D or matching placebo, QD by oral inhalation on Days 1 through 7.

    Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo

Interventions

  • Oral inhalation using a Plastiape capsule-based dry powder inhaler.

    Also known as: INS1009

  • DrugPlacebo

    Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.

06

What researchers measure

Primary outcomes

  1. Parts A and B: Number of Participants who Experienced an Adverse Event (AE)

    Safety and tolerability of single and multiple doses of treprostinil inhalation powder will be determined in healthy participants.

    Time frame: Up to Day 31 in Part A and Day 37 in Part B

Secondary outcomes

  1. Parts A and B: Area Under the Plasma Concentration Versus Time Curve (AUC) of Treprostinil

    Pharmacokinetics of treprostinil following a single and multiple doses will be assessed in healthy participants.

    Time frame: Part A: Predose and at multiple time points postdose up to Day 4; Part B: Predose and at multiple time points postdose up to Day 10

  2. Parts A and B: Area Under the Plasma Concentration Versus Time Curve (AUC) of Treprostinil Palmitil

    Pharmacokinetics of treprostinil palmitil following a single and multiple doses will be assessed in healthy participants.

    Time frame: Part A: Predose and at multiple time points postdose up to Day 4; Part B: Predose and at multiple time points postdose up to Day 10

07

Study locations

1 site
  • USA001
    Austin, Texas 78744, United States
08

References and documents

Publications

  • Ismat FA, Usansky HH, Villa R, Zou J, Teper A. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. Adv Ther. 2022 Nov;39(11):5144-5157. doi: 10.1007/s12325-022-02296-x. Epub 2022 Sep 7. PubMed 36070132 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jan 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 19, 2023
StartActual
Sep 17, 2020
Primary completionActual
Jan 12, 2021
CompletionActual
Jan 12, 2021
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091579
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Sep 17, 2020
Primary completion
Jan 12, 2021
Completion
Jan 12, 2021
Last update
Oct 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil hexadecyl ester

Start the discussion